Comparative safety and tolerability of clopidogrel and aspirin. Results from CAPRIE

Drug Safety

Volumn 21, Issue 4, 1999, Pages 325-335

  Harker, Laurence A ^a   Boissel, Jean Pierre ^b   Pilgrim, Alison J ^c   Gent, Michael ^d,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Service de Pharmacologie Clinique   (France)

^c SANOFI   (France)

^d MCMASTER UNIVERSITY   (Canada)

^e HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIAC GLYCOSIDE; CLOPIDOGREL; CORONARY VASODILATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; HORMONE; PERIPHERAL VASODILATING AGENT; PHENYTOIN;

ABDOMINAL PAIN; ADULT; AGED; APLASTIC ANEMIA; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART INFARCTION; HEMATEMESIS; HUMAN; HUMAN CELL; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MELENA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK BENEFIT ANALYSIS; SINGLE BLIND PROCEDURE; STOMACH ULCER; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

ARTERIOSCLEROSIS; ASPIRIN; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; DOUBLE-BLIND METHOD; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; NEUTROPENIA; PLATELET AGGREGATION INHIBITORS; THROMBOCYTOPENIA; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032848818     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921040-00007     Document Type: Article

References (21)

1. Murray CJL, Lopez, AD. Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436-42
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antliplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
3. Moloney BA. An analysis of the side effects of ticlopidine. In: Hass WK, Easton JD, editors. Ticlopidine, platelets and vascular disease. New York: Springer, 1993: 117-39
4. Solomon DH, Hart RG. Antithrombotic therapies for stroke prevention. Curr Opin Neurol 1994; 7: 48-53
5. Smith P, Arnesen H, Holme J. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52
6. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503
7. Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; 1: 64-8
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
9. Green D. CAPRIE trial [letter]. Lancet 1997; 349: 354-5
10. Young NS, Aplastic anaemia. Lancet 1995; 346: 228-32
11. Hass KW, Easton JD, Adams HP, et al. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7
12. Bennet CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128: 541-4
13. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999; 281: 806-10
14. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis. J Clin Gastroenterol 1995; 21: 13-6
15. Slattery J, Warlow CP, Shorrock CJ, et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509-11
16. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30
17. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77: 761-7
18. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5
19. Herbert J-M. Clopidogrel and antiplatelet therapy. Exp Opin Invest Drugs 1994; 3: 449-55
20. Cappelleri JC, Lau J, Kupelnick B, et al. Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients: a metaregression analysis. Online J Curr Clin Trials 1995; Doc. No. 174
21. Diener H, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13